Compare SWVL & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWVL | RGNT |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United Arab Emirates | Israel |
| Employees | N/A | 8 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.6M |
| IPO Year | 2021 | 2022 |
| Metric | SWVL | RGNT |
|---|---|---|
| Price | $1.42 | $2.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.6K | ★ 90.6K |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $1.23 |
| 52 Week High | $4.24 | $15.50 |
| Indicator | SWVL | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 44.94 |
| Support Level | $1.34 | $1.74 |
| Resistance Level | $1.59 | $2.27 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 46.67 | 56.13 |
Swvl Holdings Corp is a technology-driven mobility company providing mass transit solutions. It currently has two offerings: business-to-consumer (B2C) and B2B (marketed as Swvl Business). The company's B2C business utilizes its platform to provide riders with a network of minibuses and other vehicles that operate on fixed and semi-fixed routes throughout and between different cities. Riders can book available seats on vehicles to commute within a city. The Swvl Business caters to corporate customers (as well as schools and municipalities), providing them with transportation solutions for their employees and students. This business also offers transportation management software to clients who operate their own fleet. Geographically, the company generates maximum revenue from Egypt.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.